ClinicalTrials.gg
CompletedNCT06939738ASSISTUpdated Jul 20, 2026

Artificial Intelligence Scalable Solution for ST Myocardial Infarction

An observational study in Acute Myocardial Infarction (AMI), sponsored by Idoven 1903 S.L.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Idoven 1903 S.L. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
489
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in ST Elevation Myocardial Infarction with a site in Spain — 4 open to participants now, 10 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Spain.

Enrollment
8th of 14
489 · median 495
Started
2025
with 3 others
Observational
14 of 41
3 open now
Registered
36th of 41
by date
Lead sponsor
2 of 41
Idoven 1903 S.L.

Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, this one is the 8th largest by enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, and was the 36th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 41 studies in ST Elevation Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in ST Elevation Myocardial Infarction with a site in Spain, or all of them as a file.
02

Study summary

The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction (AMI).

The main objectives are to compare Willem™ performance to detect and triage ECG patterns associated with AMI compared with human ECG interpretation, and to assess the time periods for both approaches.

Read the detailed description

Delays in triage and diagnosis of patients presented with chest pain or other symptoms suggestive of Acute coronary syndrome (ACS) can be fatal. This study aims to improve those two aspects in acute ischemic disease care: reducing the delays to intervention and improving the accuracy of initial diagnosis, which are of paramount importance in cases of ACS, especially in ST-elevation myocardial infarction (STEMI). The former plays a critical role in minimizing in-hospital mortality rates, which have been shown to decrease proportionally with reduction of times to intervention. The latter relies on a correct interpretation of the ECG, first-line diagnostic tool in the assessment of patients with suspected ACS.

The current standard of care for ACS includes a 12-lead ECG that should be performed within the first 10 minutes from the first medical contact. The ECG must be interpreted by a qualified physician, who will alert the on-call cardiologist to confirm or not the activation of the "infarction code", based on the ECG and clinical presentation. Such activation will mainly entail immediate transfer of the patient to the nearest hospital with the possibility of emergency coronary angiography (if not present in the initial institution), and eventual percutaneous coronary intervention (PCI). Regarding the diagnosis of Acute Myocardial Infarction (AMI), an accurate and rapid interpretation of the first ECG is critical for the differential diagnosis between STEMI, NSTEMI or unstable angina; and follow the proper standard of care guidelines. The largest delays occurs between the first ECG and the transportation for the cardiac catheterization laboratory, which has prognostic implications.

In recent years, automatic digital tools based on artificial intelligence (AI) have been proposed as a solution to support physicians in the ECG interpretation, reducing their workload and time-to-diagnosis, suggesting the beneficial impact of AI-platforms for accurate diagnosis of AMI. In this setting, the AI-platforms should be able to automatically detect ECG patterns linked to unfavorable coronary anatomy and poor outcomes. It is also essential to have the capacity to identify more subtle ECG patterns, not obvious during physicians' interpretation, but indicating high-risk coronary anatomy. Additionally, the platform should assist the prediction of most severe coronary lesions, especially obstructive stenosis. This ability to detect coronary lesions could be useful in preventing unnecessary or premature activation of the catheterization laboratory, mainly in NSTEMI setting.

The ASSIST clinical study is a cross-sectional, multicenter study aiming to collect data to develop the Willem™ platform, an AI-based tool for ECG analysis. This plataform could improve the accuracy for AMI diagnosis, particularly the differentiation between STEMI and NSTEMI, and early identification of patients with Occlusion Myocardial Infarction (OMI).

03

Conditions studied

  • Acute Myocardial Infarction (AMI)

Keywords

  • Acute Myocardial Infarction (AMI)
  • STEMI
  • NSTEMI
  • Occlusion Myocardial Infarction (OMI)
  • AI-based ECG analysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with suspected Acute Coronary Syndrome (ACS) presenting to the emergency department and subsequently referred for angiography at the Catheterization Laboratory of the participating sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Available digitally stored 12-lead traces prior to invasive coronary angiography;
  • Available angiographic and clinical data.

Exclusion criteria

Exclusion Criteria:

  • ECGs with poor signal quality;
  • Lack of digitally stored 12-lead traces prior to coronary angiography;
  • Previous coronary events (AMI, coronary revascularizations);
  • Non-available clinical or angiographic data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
489 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Device performance

    Assessment of Willem™ diagnostic performance to detect Acute Myocardial Infarction (AMI) based on ECG analysis. The diagnostic performance metrics and their measurement units will be: * Accuracy, Sensitivity, and Specificity (%) * Positive Predictive Value (PPV) and Negative Predictive Value (NPV) (%) * F1-score (score from 0.0 to 1.0)

    Time frame: At the time of enrolment and throughout the baseline visit (single study visit)

Secondary outcomes

  1. Time assessment

    Assessment of the time needed for AMI diagnosis and for intervention (e.g. door-to-balloon time)

    Time frame: At the time of enrolment and throughout the baseline visit (single study visit)

07

Study locations

5 sites
  • Unidade Local de Saúde de São José
    Lisbon, 1169-056, Portugal
  • Unidade Local de Saúde de Lisboa Ocidental
    Lisbon, 1449-005, Portugal
  • Germans Trias i Pujol University Hospital
    Barcelona, 08916, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • La Paz University Hospital
    Madrid, 28046, Spain
08

References and documents

Individual participant data

Plan to share: Undecided — Grouped data corresponding to the clinical study objectives may be published at the end of the study. All data collected throughout the study would be included, since all clinical variables are collected per the standard of care and all relate to the two study objectives.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 23, 2025
StartActual
Apr 1, 2025
Primary completionActual
Jun 15, 2026
CompletionActual
Jun 30, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939738
Lead sponsor
Idoven 1903 S.L.
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Apr 1, 2025
Primary completion
Jun 15, 2026
Completion
Jun 30, 2026
Last update
Jul 20, 2026

Study contacts

Alfonso Jurado, MD, PhD
principal investigator · La Paz University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion